{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:00:23Z","timestamp":1792040423453,"version":"4.4.0"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T00:00:00Z","timestamp":1515456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005227","name":"Centers for Medicare and Medicaid Services","doi-asserted-by":"publisher","award":["Data Use Agreement #: 26292"],"award-info":[{"award-number":["Data Use Agreement #: 26292"]}],"id":[{"id":"10.13039\/100005227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Clinicians use tamsulosin, an \u03b11\u2010adrenoceptor antagonist, to manage symptomatic benign prostatic hyperplasia (BPH). Because \u03b11\u2010adrenoceptors are also present in the brain, the potential exists for adverse effects on cognitive functions. We explored the association between tamsulosin use and dementia risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used Medicare data (2006\u20132012) to conduct a cohort study among patients aged \u226565\u00a0years and diagnosed with BPH. Men taking tamsulosin (<jats:italic>n<\/jats:italic>\u00a0=\u00a0253\u00a0136) were matched at a 1:1 ratio using propensity\u2010scores to each of 6 comparison cohorts: patients who used no BPH\u2010medication (<jats:italic>n<\/jats:italic>\u00a0=\u00a0180\u00a0926), and patients who used the following alternative\u2010BPH\u2010medications: doxazosin (<jats:italic>n<\/jats:italic>\u00a0=\u00a028\u00a0581), terazosin (<jats:italic>n<\/jats:italic>\u00a0=\u00a023\u00a0858), alfuzosin (<jats:italic>n<\/jats:italic>\u00a0=\u00a017\u00a0934), dutasteride (<jats:italic>n<\/jats:italic>\u00a0=\u00a034\u00a0027), and finasteride (<jats:italic>n<\/jats:italic>\u00a0=\u00a038\u00a0767). Assessment began following the first fill of BPH\u2010medication to identify incident dementia by ICD\u20109 diagnosis codes. We estimated hazard ratios (HR) and 95% confidence intervals (CI) for dementia using Cox proportional hazard regression for each of the 6 propensity\u2010score\u2010matched cohort\u2010pairs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median follow\u2010up period for all cohorts was 19.8\u00a0months. After propensity\u2010score matching, the tamsulosin cohort had an incidence of dementia of 31.3\/1000 person\u2010years compared with only 25.9\/1000 person\u2010years in the no\u2010BPH\u2010medication cohort. The risk of dementia was significantly higher in the tamsulosin cohort, when compared with the no\u2010BPH\u2010medication cohort (HR [95% CI]: 1.17 [1.14, 1.21]) and each of the alternative\u2010BPH\u2010medication cohorts: doxazosin (1.20 [1.12, 1.28]), terazosin (1.11 [1.04, 1.19]), alfuzosin (1.12 [1.03, 1.22]), dutasteride (1.26 [1.19, 1.34]), and finasteride (1.13 [1.07, 1.19]). The significance of these findings persisted in sensitivity analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Tamsulosin may increase the risk of dementia in older men with BPH.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4361","type":"journal-article","created":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T12:29:58Z","timestamp":1515587398000},"page":"340-348","source":"Crossref","is-referenced-by-count":75,"title":["Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia"],"prefix":"10.1002","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8680-877X","authenticated-orcid":false,"given":"Yinghui","family":"Duan","sequence":"first","affiliation":[{"name":"Department of Community Medicine and Health Care University of Connecticut Health Center Farmington CT USA"},{"name":"Connecticut Institute for Clinical and Translational Science (CICATS), Farmington CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Grady","sequence":"additional","affiliation":[{"name":"Department of Community Medicine and Health Care University of Connecticut Health Center Farmington CT USA"},{"name":"Connecticut Institute for Clinical and Translational Science (CICATS), Farmington CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Albertsen","sequence":"additional","affiliation":[{"name":"Department of Surgery (Urology) University of Connecticut Health Center Farmington CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Helen Wu","sequence":"additional","affiliation":[{"name":"Connecticut Institute for Clinical and Translational Science (CICATS), Farmington CT USA"},{"name":"Department of Psychiatry University of Connecticut Health Center Farmington CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,9]]},"reference":[{"issue":"4","key":"e_1_2_12_2_1","first-page":"181","article-title":"Alpha blockers for the treatment of benign prostatic hyperplasia","volume":"9","author":"Lepor H","year":"2007","journal-title":"Rev Urol"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.01.074"},{"key":"e_1_2_12_4_1","first-page":"S3","article-title":"Benign prostatic hyperplasia: an overview","volume":"7","author":"Roehrborn CG","year":"2005","journal-title":"Rev Urol"},{"key":"e_1_2_12_5_1","unstructured":"Food and Drug Administration.Pediatric focused safety review: Flomax\u00ae(tamsulosin hydrochloride). Center for Drug Evaluation and Research FDA: Pediatric Advisory Committee Meeting 2012. (Accessed June 13 2016 athttp:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/PediatricAdvisoryCommittee\/UCM289947.pdf)"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000076140.68657.fd"},{"key":"e_1_2_12_7_1","first-page":"S42","article-title":"Long\u2010term efficacy and safety of tamsulosin for benign prostatic hyperplasia","volume":"7","author":"Narayan P","year":"2005","journal-title":"Rev Urol"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/10799893.2010.550008"},{"issue":"14","key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"9474","DOI":"10.1073\/pnas.132552699","article-title":"Knockout of the alpha 1A\/C\u2010adrenergic receptor subtype: the alpha 1A\/C is expressed in resistance arteries and is required to maintain arterial blood pressure","volume":"99","author":"Rokosh DG","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.21.11589"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200214001"},{"issue":"1","key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0022-3565(24)36764-3","article-title":"Comparative alpha\u20101 adrenoceptor subtype selectivity and functional uroselectivity of alpha\u20101 adrenoceptor antagonists","volume":"282","author":"Martin DJ","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000052349"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2009.06.035"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.111.073734"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2007.01.031"},{"issue":"2","key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1464-410X.2006.06104.x","article-title":"Impact of medical treatments for benign prostatic hyperplasia on sexual function","volume":"97","author":"Giuliano F","year":"2006","journal-title":"BJU Int"},{"issue":"4","key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.18433\/J3JK5P","article-title":"Partial least square and hierarchical clustering in ADMET modeling: prediction of blood\u2010brain barrier permeation of \u03b1\u2010adrenergic and imidazoline receptor ligands","volume":"16","author":"Nikolic K","year":"2013","journal-title":"J Pharm Pharm Sci"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e32816ebc7b"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(02)00452-3"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1062860606288243"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1086\/511640"},{"key":"e_1_2_12_23_1","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology.Guidelines for ATC classification and DDD assignment 2015. Oslo 2015."},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/154.9.854"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003833"},{"key":"e_1_2_12_27_1","unstructured":"ParsonsLS.Reducing bias in a propensity score matched\u2010pair sample using greedy matching techniques. In: Proceedings of the Twenty\u2010sixth Annual SAS Users group international conference; 2001: SAS Institute Inc Cary NC;2001."},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2006.pto_293.x"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_2_12_30_1","unstructured":"AllisonPD.Survival analysis using SAS: a practical guide: SAS Institute;2010."},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2006.10.009"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyr218"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.12.007"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-009-1248-6"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.3.728"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2008.06.013"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.09.035"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000974"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4361","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T18:17:11Z","timestamp":1751221031000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,9]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/pds.4361"],"URL":"https:\/\/doi.org\/10.1002\/pds.4361","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,9]]}}}